Gam-COVID-Vac

Algeria has become the first country in Africa to register Sputnik V vaccine

Retrieved on: 
Sunday, January 10, 2021
Medicine, COVID-19 pandemic in Russia, Gam-COVID-Vac, Science and technology in Russia, Medical specialties, Kirill Dmitriev, Russian Direct Investment Fund, Health, Vaccination, Virology, Vaccine, COVID-19 vaccine

Supplies of the vaccine to Algeria will be facilitated by international partners of RDIF in India, China, South Korea and other countries.

Key Points: 
  • Supplies of the vaccine to Algeria will be facilitated by international partners of RDIF in India, China, South Korea and other countries.
  • Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said:
    "RDIF welcomes the first registration of Sputnik V vaccine in Africa.
  • Sputnik V was registered thanks to a number of key advantages:
    Efficacy of Sputnik V is over 90%, with full protection against severe cases of COVID-19.
  • The Sputnik V vaccine has been approved in Russia, Belarus, Serbia, Argentina, Bolivia, the process to approve the vaccine in the EU has been initiated.

Belarus starts vaccination with Sputnik V

Retrieved on: 
Tuesday, December 29, 2020
Health sciences, Clinical research, Design of experiments, Articles, Health, COVID-19 pandemic in Russia, Gam-COVID-Vac, Science and technology in Russia, Clinical trial, Sputnik, Russian Direct Investment Fund, Vaccination

Belarus was the first country to officially register Sputnik V after Russia.

Key Points: 
  • Belarus was the first country to officially register Sputnik V after Russia.
  • On October 1, Belarus was also the first foreign country to begin clinical trials of Sputnik V. Vaccination of volunteers was conducted as part of double-blind, randomized, placebo-controlled clinical trials in eight medical institutions selected as research centers in Belarus.
  • RDIF and its partners are jointly working on establishing local production of Sputnik V in Belarus.
  • Today Belarus has also become the first country to start vaccination with Sputnik V outside Russia.

Sheremetyevo International Airport Manages First Shipment Of Sputnik V Vaccine To Argentina

Retrieved on: 
Monday, December 28, 2020
Medicine, Medical research, Health sciences, Health, COVID-19 vaccine, Gam-COVID-Vac, Vaccine, Tozinameran

MOSCOW, Dec. 28, 2020 /PRNewswire/ -- Sheremetyevo International Airport once again managed the logistics of delivering the Sputnik V coronavirus vaccine on December 24 when the Russian Direct Investment Fund shipped the first batch of 300,000 doses of the vaccine to Argentina through Sheremetyevo's cargo facilities.

Key Points: 
  • MOSCOW, Dec. 28, 2020 /PRNewswire/ -- Sheremetyevo International Airport once again managed the logistics of delivering the Sputnik V coronavirus vaccine on December 24 when the Russian Direct Investment Fund shipped the first batch of 300,000 doses of the vaccine to Argentina through Sheremetyevo's cargo facilities.
  • This delivery of the world's first coronavirus vaccine is first of 10 million doses the Government of Argentina will receive.
  • The supply of 300,000 doses to Argentina is one of the largest single shipments of a COVID vaccine to any country in Latin America.
  • Argentina is the first country in Latin America to officially authorize the use of Sputnik V vaccine.

Argentina Receives the First Shipment of Russia’s Sputnik V Vaccine

Retrieved on: 
Monday, December 28, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Science and technology in Russia, COVID-19 pandemic in Russia, Gam-COVID-Vac, Medical specialties, Gamaleya, Medicine, Vaccination, Russian Direct Investment Fund, Vaccine, Sputnik 1

The first batch of the Sputnik V vaccine developed by Russian scientists from the Gamaleya National Center of Epidemiology and Microbiology with the support of the Russian Direct Investment Fund (RDIF) has been delivered to Argentina.

Key Points: 
  • The first batch of the Sputnik V vaccine developed by Russian scientists from the Gamaleya National Center of Epidemiology and Microbiology with the support of the Russian Direct Investment Fund (RDIF) has been delivered to Argentina.
  • The possibility of producing the Sputnik V vaccine in Argentina was first discussed during a September meeting of the co-chairs of the Intergovernmental Russian-Argentine Commission of Trade-Economic and Scientific-Technical Cooperation.
  • The delivery of the Sputnik V vaccine to Argentina is a truly historic moment and an excellent example of cooperation between our countries.
  • The "V" in the name of our vaccine stands for "Victory, and we wish the people of Argentina a decisive victory over this disease.

First batch of 300,000 doses of Sputnik V vaccine delivered to Argentina

Retrieved on: 
Thursday, December 24, 2020
Medicine, Health sciences, Articles, COVID-19 vaccine, Medical research, Gam-COVID-Vac, Vaccine, Russian Direct Investment Fund, Sputnik

MOSCOW, Dec. 24, 2020 /PRNewswire/ --The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) announces the delivery of the first batch of 300,000 doses of Sputnik V, the world's first registered vaccine against coronavirus, to Argentina.

Key Points: 
  • MOSCOW, Dec. 24, 2020 /PRNewswire/ --The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) announces the delivery of the first batch of 300,000 doses of Sputnik V, the world's first registered vaccine against coronavirus, to Argentina.
  • The supply of 300,000 doses to Argentina is one of the largest single shipments of a COVID vaccine to any country in Latin America.
  • Sputnik V has a unique set of parameters making it one of the most competitive vaccines globally.
  • "Argentina has become the first country in Latin America to officially authorize the use of Sputnik V vaccine.

RDIF, The Gamaleya National Center, AstraZeneca and R-Pharm sign an agreement to cooperate on COVID-19 vaccine development

Retrieved on: 
Monday, December 21, 2020
Medicine, Branches of biology, Biology, COVID-19 pandemic in Russia, Gam-COVID-Vac, Science and technology in Russia, Viral vector, Vaccine, AZD1222, Adenoviridae, Bavarian Nordic

The agreement was announced on a video-conference with Vladimir Putin, the President of Russia.

Key Points: 
  • The agreement was announced on a video-conference with Vladimir Putin, the President of Russia.
  • Clinical trials of the combination of AZD1222 vaccine with Sputnik V's human adenoviral vector type Ad26 will begin soon.
  • The regimen with two different adenoviral vectors for a prime and a boost immunization is a unique and ground-breaking discovery of the Gamaleya Center scientists.
  • This regimen is one of the reasons why the vaccine shows efficacy of over 90%, with 100% efficacy in severe cases.

RDIF, The Gamaleya National Center, AstraZeneca and R-Pharm sign an agreement to cooperate on COVID-19 vaccine development

Retrieved on: 
Monday, December 21, 2020
Medicine, Branches of biology, Biology, COVID-19 pandemic in Russia, Gam-COVID-Vac, Science and technology in Russia, Viral vector, Vaccine, AZD1222, Adenoviridae, Bavarian Nordic

The agreement was announced on a video-conference with Vladimir Putin, the President of Russia.

Key Points: 
  • The agreement was announced on a video-conference with Vladimir Putin, the President of Russia.
  • Clinical trials of the combination of AZD1222 vaccine with Sputnik V's human adenoviral vector type Ad26 will begin soon.
  • The regimen with two different adenoviral vectors for a prime and a boost immunization is a unique and ground-breaking discovery of the Gamaleya Center scientists.
  • This regimen is one of the reasons why the vaccine shows efficacy of over 90%, with 100% efficacy in severe cases.

The Sputnik V vaccine's efficacy is confirmed at 91.4% based on data analysis of the final control point of clinical trials

Retrieved on: 
Monday, December 14, 2020
Medicine, Medical specialties, Vaccination, Vaccines, Health care, COVID-19 pandemic in Russia, Gam-COVID-Vac, Science and technology in Russia, Vaccine, COVID-19 vaccine, Vaccine efficacy

High efficacy rate of the vaccine above 90% was confirmed at each of the three control points of clinical trials the calculated efficacy rate of the Sputnik V vaccine at the first control point (20 cases) was 92% and 91.4% at the second point (39 cases).

Key Points: 
  • High efficacy rate of the vaccine above 90% was confirmed at each of the three control points of clinical trials the calculated efficacy rate of the Sputnik V vaccine at the first control point (20 cases) was 92% and 91.4% at the second point (39 cases).
  • Based on the data obtained at the third control point the Gamaleya Center will create a report that will be used to submit for accelerated registration of the Sputnik V vaccine in various countries.
  • "The data analysis at the third and final control point of the Sputnik V vaccine clinical trials confirmed the efficacy of the vaccine of over 90%.
  • Detailed information on the Sputnik V vaccine, its human adenoviral vectors technological platform, and other details are available at sputnikvaccine.com .

AstraZeneca will test using component of Russia's Sputnik V in clinical trials of its own vaccine against coronavirus

Retrieved on: 
Friday, December 11, 2020
Medicine, Vaccines, Medical specialties, Drugs, COVID-19 pandemic in Russia, Gam-COVID-Vac, Science and technology in Russia, Vaccine, AstraZeneca, COVID-19 vaccine, AZD1222

This approach provides for a stronger and longer-term immune response compared with vaccines using the same component for both inoculations.

Key Points: 
  • This approach provides for a stronger and longer-term immune response compared with vaccines using the same component for both inoculations.
  • On November 23, 2020, following results which showed high efficacy for the Sputnik V vaccine, RDIF and the Gamaleya Center offered AstraZeneca the use of one of the two components of the Sputnik V vaccine.
  • AstraZeneca accepted the proposal by RDIF and the Gamaleya Center to use one of the two vectors of the Sputnik V vaccine in additional clinical trials of its own vaccine, which will commence before the end of this year.
  • AstraZeneca accepted RDIF's proposal and will begin clinical trials of its vaccine in combination with Sputnik V's human adenoviral vector type Ad26 by the end of 2020.

RDIF and Government of Argentina have signed a contract to supply 10 million doses of the Sputnik V vaccine

Retrieved on: 
Thursday, December 10, 2020
Medical specialties, Russian Direct Investment Fund, Vaccination, Medicine, Gam-COVID-Vac, Vaccine, Kirill Dmitriev, COVID-19 vaccine

MOSCOW, Dec. 10, 2020 /PRNewswire/ --The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) andthe Government of Argentina have signed a contract to supply to the country 10 million doses of Sputnik V, the world's first registered vaccine against coronavirus.

Key Points: 
  • MOSCOW, Dec. 10, 2020 /PRNewswire/ --The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) andthe Government of Argentina have signed a contract to supply to the country 10 million doses of Sputnik V, the world's first registered vaccine against coronavirus.
  • Supplies of the vaccine will be facilitated by international partners of RDIF in India, China, South Korea and other countries.
  • The cost of one dose of the Sputnik V vaccine for international markets will be less than $10.
  • Requests for more than 1.2 billion doses of Sputnik V vaccine came from more than 50 countries.